Voyager Therapeutics Inc. (NASDAQ:VYGR) – Stock analysts at Wedbush boosted their FY2016 EPS estimates for shares of Voyager Therapeutics in a research report issued to clients and investors on Thursday. Wedbush analyst D. Nierengarten now expects that the brokerage will post earnings of ($1.39) per share for the year, up from their previous forecast of ($1.46). Wedbush has a “Outperform” rating and a $36.00 price objective on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q4 2016 earnings at ($0.37) EPS, Q1 2017 earnings at ($0.39) EPS, Q2 2017 earnings at ($0.40) EPS, Q3 2017 earnings at ($0.42) EPS, Q4 2017 earnings at ($0.43) EPS, FY2017 earnings at ($1.64) EPS, FY2018 earnings at ($1.95) EPS, FY2019 earnings at ($2.41) EPS and FY2020 earnings at ($2.61) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. Voyager Therapeutics had a negative net margin of 195.31% and a negative return on equity of 20.15%.

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

A number of other brokerages also recently weighed in on VYGR. Zacks Investment Research downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 26th. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday. Finally, Piper Jaffray Cos. set a $37.00 target price on Voyager Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 11th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.80.

Shares of Voyager Therapeutics (NASDAQ:VYGR) opened at 12.24 on Monday. The firm has a 50-day moving average price of $12.15 and a 200 day moving average price of $12.92. Voyager Therapeutics has a 1-year low of $8.12 and a 1-year high of $30.54. The company’s market cap is $327.15 million.

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Voyager Therapeutics by 1,487.3% in the second quarter. Vanguard Group Inc. now owns 312,593 shares of the company’s stock worth $3,436,000 after buying an additional 292,900 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Voyager Therapeutics by 171.3% in the second quarter. JPMorgan Chase & Co. now owns 288,425 shares of the company’s stock worth $3,170,000 after buying an additional 182,125 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Voyager Therapeutics by 106.8% in the second quarter. BlackRock Fund Advisors now owns 302,971 shares of the company’s stock worth $3,330,000 after buying an additional 156,443 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Voyager Therapeutics during the first quarter worth about $873,000. Finally, State Street Corp boosted its stake in shares of Voyager Therapeutics by 147.1% in the second quarter. State Street Corp now owns 142,611 shares of the company’s stock worth $1,565,000 after buying an additional 84,906 shares during the last quarter. 39.65% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

5 Day Chart for NASDAQ:VYGR

Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.